Feng Yan, Han Xiaolei, Zhang Zhe, Qiao Han, Tang Huaping
1 Department of Respiratory Medicine, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
2 Department of Health Office, Qingdao Municipal Hospital, Qingdao, China.
Front Genet. 2023 Jan 19;13:1085785. doi: 10.3389/fgene.2022.1085785. eCollection 2022.
The primary factor of cancer mortality is lung tumor. ABI3BP gene encodes an extracellular matrix bind protein associated to multiplication and derivation. However, the prognosis score of ABI3BP for lung tumor and its relation with immunity cellular infiltration for lung tumor have not been reported. Public repository systems (Timer, GEPIA, TCGA, HPA) were utilized to explore expression of ABI3BP for lung tumor, and explored the relation of ABI3BP and clinicopathological parameters. TCGA information set was utilized for cox analysis for data with one or more variables of ABI3BP for lung tumor. STRING was utilized to explore ABI3BP regulatory networks. GO/KEGG enrichment analysis as well as enrichment analysis of gene sets were carried out for ABI3BP co-expression R package. And finally we explored the relation of expression of ABI3BP and lung tumor immunity invasion, exploring the influence of ABI3BP level of expression on immunotreatment and whether immunity invasion would affect the prognosis of patients with lung tumor. ABI3BP is downregulated in LUAD and LUSC, and associated to lung tumor phase and prognosis. Univariate and multivariate cox regression showed that ABI3BP was an independent prognostic factor in patients with lung tumors. The extracellular matrix protein-coding gene and the ABI3BP-related gene were intersected to obtain 10 hub genes. On the basis of GO/KEGG enrichment analysis, hub genes are closely associated to immunity-associated pathways including T cell receptor signaling pathway, immune response-activating cell surface receptor signaling pathway. Finally, the expression of ABI3BP is closely related to immune cell infiltration and immune cell marker set, and the expression of ABI3BP can help predict the therapeutic effect of immune checkpoint inhibitors and improve the prognosis of patients. ABI3BP could be a new target for lung tumor that could be utilized as a diagnostic and therapeutic tool.
癌症死亡的主要因素是肺肿瘤。ABI3BP基因编码一种与增殖和分化相关的细胞外基质结合蛋白。然而,ABI3BP对肺肿瘤的预后评分及其与肺肿瘤免疫细胞浸润的关系尚未见报道。利用公共数据库系统(Timer、GEPIA、TCGA、HPA)探索ABI3BP在肺肿瘤中的表达,并探讨ABI3BP与临床病理参数的关系。利用TCGA信息集对肺肿瘤中具有一个或多个ABI3BP变量的数据进行cox分析。利用STRING探索ABI3BP调控网络。对ABI3BP共表达R包进行GO/KEGG富集分析以及基因集富集分析。最后,我们探讨了ABI3BP表达与肺肿瘤免疫侵袭的关系,探讨了ABI3BP表达水平对免疫治疗的影响以及免疫侵袭是否会影响肺肿瘤患者的预后。ABI3BP在肺腺癌(LUAD)和肺鳞癌(LUSC)中表达下调,并与肺肿瘤分期和预后相关。单因素和多因素cox回归显示,ABI3BP是肺肿瘤患者的独立预后因素。将细胞外基质蛋白编码基因与ABI3BP相关基因进行交集分析,得到10个枢纽基因。基于GO/KEGG富集分析,枢纽基因与包括T细胞受体信号通路、免疫反应激活细胞表面受体信号通路在内的免疫相关通路密切相关。最后,ABI3BP的表达与免疫细胞浸润和免疫细胞标志物集密切相关,ABI3BP的表达有助于预测免疫检查点抑制剂的治疗效果并改善患者预后。ABI3BP可能成为肺肿瘤的一个新靶点,可作为诊断和治疗工具。